/MBCI

MBCI Stock - MabCure, Inc.

Q: What is the analyst price target for MBCI?

Analyst price target information is not currently available for MBCI.

Q: What is MBCI's market cap?

Market capitalization information is not currently available for MBCI.

Energy|Solar|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for MBCI

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2007

FY2008

FY2009

FY2010

FY2011

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta7.91

52W High$0.00

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2011	FY2010	FY2009	FY2008	FY2007
Revenue	$500,000	N/A	N/A	N/A	N/A
Gross Profit	$500,000	N/A	N/A	N/A	N/A
Gross Margin	100.0%	N/A	N/A	N/A	N/A
Operating Income	$-709,745	$-1,019,420	$-1,359,495	$-535,964	$-106,265
Net Income	$-12,451,496	$-1,432,654	$-1,388,637	$-531,478	$-106,265
Net Margin	-2490.3%	N/A	N/A	N/A	N/A
EPS	$-0.20	$-0.02	$-0.02	$-0.01	$-0.00

Company Overview

MabCure Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure Inc. in January 2008 to reflect its new business plan. MabCure Inc. was founded in 2006 and is based in White Plains, New York.